Company Focus
Merck & Co
Latest Merck & Co News
Pharmaceutical
A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 signals a departure from the initial vaccine slate. New appointees named by Health and Human Services Secretary Robert F. Kennedy Jr dismantled the previous committee structure two days after dismissing all 17 members. 20 June 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Merck & Co
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread within the lungs or to other parts of the body. 21 June 2025
Pharmaceutical
US healthcare group Abbott has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize pharmaceutical manufacturing, develop biosimilars, and accelerate digital transformation, as the emirate deepens its bid to become a regional powerhouse in the global life sciences sector. 20 June 2025
Biotechnology
Danish vaccine specialist Bavarian Nordic is set to collect $160 million from the sale of a US priority review voucher (PRV) earned through the approval of its chikungunya vaccine, Vimkunya (chikungunya vaccine), marking one of the highest prices paid for a PRV in recent years. 20 June 2025
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 to 49 years at increased risk of severe RSV disease. 20 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Pharmaceutical
Japanese drugmaker Mochida Pharmaceutical announced that Thien Thao Pharmaceutical Joint Stock Company, a partner of Meiji, has obtained approval to import and market Epadel S, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan, for the treatment of hypertriglyceridemia in Vietnam. 20 June 2025
Pharmaceutical
A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 signals a departure from the initial vaccine slate. New appointees named by Health and Human Services Secretary Robert F. Kennedy Jr dismantled the previous committee structure two days after dismissing all 17 members. 20 June 2025
Biotechnology
Sanofi has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine development and manufacturing in the United Arab Emirates. 19 June 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Gilead Sciences Yeztugo (lenacapavir) - the company’s injectable HIV-1 capsid inhibitor - as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. 19 June 2025
Biotechnology
The US Food and Drug Administration has approved US biotech Incyte’s Monjuvi (tafasitamab-cxix) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). 19 June 2025
Latest In Brief for Merck & Co
Biosimilars
The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting. 20 June 2025
Latest Related Ones To Watch News
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
16 June 2025
12 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze